SCHEMBL3132346

SCHEMBL3132346

COc1ccc(N(Cc2cnccn2)c2ccc(C(=O)O)cc2)cc1OC(F)F

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.40
RXRA P19793 9/20 0.39
RXRB P28702 2/20 0.39
RXRG P48443 2/20 0.39
KMT2A Q03164 1/20 0.39
SLC5A7 Q9GZV3 1/20 0.39
GAA P10253 2/20 0.38
FGFR1 P11362 1/20 0.38
FGFR2 P21802 1/20 0.38
FGFR4 P22455 1/20 0.38
FGFR3 P22607 1/20 0.38
KDR P35968 1/20 0.38
KDM4E B2RXH2 1/20 0.37
HTT P42858 1/20 0.37
PPARG P37231 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
F11 P03951 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3122655 0.96 SYK (0.40) SYKRXRARXRBRXRGKMT2A
SCHEMBL3120621 0.94 PDE4A (0.40) SYKRXRARXRBRXRGGAA
SCHEMBL3129425 0.94 SYK (0.38) SYKRXRARXRBRXRGKMT2A
SCHEMBL3126333 0.91 RXRA (0.48) RXRARXRBRXRGGAAPPARG
SCHEMBL3128010 0.90 RXRA (0.43) RXRARXRBRXRGKMT2AKDM4E
SCHEMBL3200145 0.88 SYK (0.37) SYKKMT2ASLC5A7GAAFGFR1
SCHEMBL3131421 0.88 SYK (0.45) SYKRXRAKMT2AGAAFGFR1
SCHEMBL3129434 0.86 KMT2A (0.37) SYKKMT2ASLC5A7GAAFGFR1
SCHEMBL3132484 0.85 PDE4D (0.39) SYKRXRAKMT2AGAA
SCHEMBL3131330 0.85 ALDH1A1 (0.46) HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B SYK 2747/4885RXRA 2856/4885RXRB 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.